超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

加拿大GeneNews
GeneNews專注于開發基于血液的疾病早期診斷和個性化健康管理的生物標志物測試。
在泰達成立股份公司，開發基于血液樣品RNA的癌癥診斷試劑盒。

GeneNews Limited (formerly ChondroGene Limited) was formed in 1998 by its two founders; Dr. K. Wayne Marshall, a noted orthopaedic surgeon and knee specialist and Dr. C.C. Liew, an internationally recognized leader in the area of tissue-specific functional genomics.

GeneNews was founded to focus on the identification of novel therapeutic targets for a single disease, osteoarthritis. At that time, the company was interested in the gene expression of cartilage cells called chondrocytes, hence the name ChondroGene. The goal was to examine how the tissues of the joint function in different stages of osteoarthritis; from normal joints, to moderately diseased joints, all the way to severe osteoarthritis which can be treated only by total joint replacement. Genenews’ work on Osteroarthritis led to two collaborations with Pfizer Inc.

Going forward, our ability to generate biomarker content based on the Sentinel Principle and Discovery Funnel will enable development of a broad range of Sentry tests and related applications. These gene-based tests and the genomic information gained from our discovery pipeline will provide a continuing stream of novel information or "news" across a broad range of diseases and clinical questions. Given these considerations, the company decided it was appropriate to change its’ name to GeneNews.

GeneNews Limited is an Ontario incorporated company headquartered in Toronto. The active business and operations are conducted through a wholly-owned subsidiary, GeneNews Corporation. GeneNews has a single class of common shares that are listed for trading on the TSX Exchange under the stock symbol "GEN".